Evofem Biosciences, Inc. Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

Evofem Biosciences, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $19.36 million for the year ending 2024.

  • Evofem Biosciences, Inc. showed an increase of +6.3% in Revenue From Contract With Customer Excluding Assessed Tax from 2023 to 2024.
  • This data is from Evofem Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
  • XBRL data for this metric is available from 2022 to 2024 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 3 years of available data (2022 to 2024), Evofem Biosciences, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 15.0%.
  • Historical annual values: Fiscal year 2024: $19.36 million | Fiscal year 2023: $18.22 million | Fiscal year 2022: $16.84 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: